Status
Ongoing
Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Status
Ongoing
Classification
Class I
Report Date
May 10, 2023
Termination Date
—